American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Bajorin
    Bajorin
  4. Morris
    Morris
  5. Rosenberg
    Rosenberg
  6. Solit
    Solit
  7. Feldman
    Feldman
  8. Voss
    Voss
  9. Berger
    Berger
  10. Iyer
    Iyer

Groups

  1. Genitourinary Oncology Service (1607)
  2. Solid Tumor Oncology Division (1607)
  3. Department of Medicine (1602)
  4. GSK Faculty (318)
  5. Epidemiology and Biostatistics (299)
  6. Surgery (275)
  7. Survivorship Research (252)
  8. Biostatistics Service (237)
  9. Urology (228)
  10. Human Oncology and Pathogenesis Program (217)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (1266)
  2. Journal Article (327)
  3. Correspondence (6)
  4. Editorial (5)
  5. Review (2)
  6. Guidelines (1)
Groups
  1. Genitourinary Oncology Service (1607)
  2. Solid Tumor Oncology Division (1607)
  3. Department of Medicine (1602)
  4. GSK Faculty (318)
  5. Epidemiology and Biostatistics (299)
  6. Surgery (275)

More Groups

People
  1. Robert Motzer (418)
  2. Howard Scher (329)
  3. Dean Bajorin (266)
  4. Michael Morris (223)
  5. Jonathan Rosenberg (182)
  6. David Solit (168)

More People

Years
  1. 2024 (5)
  2. 2023 (114)
  3. 2022 (106)
  4. 2021 (108)
  5. 2020 (124)
  6. 2019 (108)

More Years

Publications
  1. Journal of Clinical Oncology (1559)
  2. JCO Precision Oncology (24)
  3. Journal of Oncology Practice (12)
  4. American Society of Clinical Oncology Educational Book (8)
  5. JCO Clinical Cancer Informatics (3)
  6. JCO Global Oncology (1)

Results (1607)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J.; Goh, J. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
    Journal Article

    Aggarwal, R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T.; Appleman, L.; Weckstein, D.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Radiographic progression-free survival and clinical progression-free survival as potential surrogates for overall survival in men with metastatic hormone-sensitive prostate cancer
    Journal Article

    Halabi, S.; Roy, A.; Rydzewska, L.; Guo, S.; Godolphin, P.; Hussain, M.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship
    Review

    Travis, L. B.; Feldman, D. R.; Fung, C.; Poynter, J. N.; Lockley, M.; Frazier, A. L.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: A multicenter, randomized phase II clinical trial
    Journal Article

    Gillespie, E. F.; Yang, J. C.; Mathis, N. J.; Marine, C. B.; White, C.; Zhang, Z.; Barker, C. A.; Kotecha, R.; McIntosh, A.; Vaynrub, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Targeted molecular profiling of circulating cell-free DNA in patients with advanced hepatocellular carcinoma
    Journal Article

    Cowzer, D.; White, J. B.; Chou, J. F.; Chen, P. J.; Kim, T. H.; Khalil, D. N.; El Dika, I. H.; Columna, K.; Yaqubie, A.; Light, J. S.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase II multicenter trial of abiraterone acetate with or without cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Slovin, S. F.; Knudsen, K.; Halabi, S.; de Leeuw, R.; Shafi, A.; Kang, P.; Wolf, S.; Luo, B.; Gopalan, A.; Curley, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer
    Journal Article

    O'Donnell, P. H.; Milowsky, M. I.; Petrylak, D. P.; Hoimes, C. J.; Flaig, T. W.; Mar, N.; Moon, H. H.; Friedlander, T. W.; McKay, R. R.; Bilen, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A multi-center natural history study of precision-based genomics in prostate cancer (PC)
    Meeting Abstract

    Beltran, H.; Mateo, J.; Abida, W.; McKay, R. R.; Montgomery, R.t B.; Aggarwal, Rahul Raj; Lee-Wisdom, K.; Figg, W. D.; Dahut, W. L.; Karzai, F.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, A. O.; Saad, F.; Reid, A. H.; Sakharova, O. V.; Feng, F. Y.; Fizazi, K.; Morris, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save